Why the study?
Bortezomib and melphalan do not typically cause cardiotoxicity, making it important to identify and understand the cardiac implications of newer chemotherapeutic agents.
This case highlights the potential for bortezomib and melphalan to induce partially reversible cardiomyopathy, emphasizing the need for vigilance regarding atypical cardiotoxicity of chemotherapeutic agents.
Answers are grounded in this paper and cite their sources.
Bortezomib-melphalan may cause partially reversible cardiomyopathy presenting as sinus tachycardia; hypothesis-generating case leaves open need for prospective cardiac safety data.
Chemotherapy-induced cardiotoxicity is a known condition, however, bortezomib and melphalan do not typically cause cardiotoxicity. With the rise in the use of newer chemotherapeutic agents, it is important to identify and understand the cardiac implications of chemotherapeutic agents. We present a case of a 70-year-old female with no known significant cardiac history presenting with partially reversible cardiomyopathy with initial presentation only being as sinus tachycardia.
No takes yet. Share an insight, caveat, or question.
Sampat et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: